Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1990 Sep;116(5):453–458. doi: 10.1007/BF01612993

Sensitivity of rodent osteosarcoma clones to platinum-containing phosphonic acid complexes in vitro

T Klenner 1,✉, P Valenzuela-Paz 1, B K Keppler 2, H R Scherf 1
PMCID: PMC12201860  PMID: 2229134

Abstract

Osteosarcoma treatment still is unsatisfactory owing to the development of metastases. This situation causes many problems for the patients as well as the clinicians. Tumor heterogeneity is made responsible for the development of cell lines resistant to chemotherapy. As the transplantable osteosarcoma of the rat resembles the human metastasizing osteosarcoma, studies on clones of this tumor were started. The following compounds were investigated: AMDP,cis-diammine[nitrilotris(methylphosphonato)(2-)-O 1,N 1]platinum II; DADP,cis-cydohexane-1,2-diamine[nitrilotris(methylphosphonato)(2-)-O 1,N 1]-platinum II; IMD,cis-diammine[iminobis(methylphosphonato)(2-)-O 1,N 1]platinum II; DIMD,cis-cyclohexane-1,2-diamine[iminobis(methylphosphonato) (2-)-O 1,N 1]platinum II. In vitro assays were performed with cell lines derived from a lung metastasis with the limited-dilution method. The clones varied in modal chromosome number, growth kinetics and tumorigenicity. AMDP was the most potent compound in all three clones resulting in a concentration- and time-dependent effect while IMD was somewhat less active. The diamminocyclohexane derivatives were considerably less effective, inhibiting cell growth especially in clone C10. In contrast, clone C36 was more sensitive than C25 and did not recover within the observation period of 5 days. Viability was reduced significantly only in C10, when treated with AMDP. Differences between the clones and the various compounds in inhibiting cell growth could be observed. Therefore, further experiments on the heterogeneity and sensitivity of these cell lines seem promising.

Key words: Cisplatin-containing phosphonic acids, Osteosarcoma cell clones, In vitro studies

References

  1. Angres G, Scherf HR (1989) Different effects of cyclophosphamide in vivo and phosphamide mustard in vitro on two cell clones of chemically induced mammary carcinoma of the rat. J Cancer Res Clin Oncol 115:2, 203–206 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beron G, Winkler K, Beck J, Berthold F, Branders W, Gerein K, Havers W, Henze G et al. (1988) Prognosis after metastasis in osteocarcoma: experience from the COSS studies. Contrib Oncol 30:143–149 [Google Scholar]
  3. Bergerat J-P, Barlogie B, Drewinko B (1979) Effects ofcis-dichlorodiammineplatinum (II) on human colon carcinoma cells in-vitro. Cancer Res 39:1134–1338 [PubMed] [Google Scholar]
  4. Burchenal JH, Kalaher K, Dew K, Lokys L (1979) Rationale for development of platinum analogs. Cancer Treat Rep 63:1493–1498 [PubMed] [Google Scholar]
  5. Dexter DL, Spremulli EN, Fligiel S, Barbosa JA, Vogel G, Van Voorhees B, Calabresi P (1981) Heterogeneity of cancer cells from a single human colon carcinoma. Am J Med 71:949–956 [DOI] [PubMed] [Google Scholar]
  6. Drewinko B, Brown BW, Gottlieb JA (1973) The effect ofcis-dichlorodiammineplatinum (II) on cultured human lymphoma cells and its therapeutic implications. Cancer Res 33:3091–3095 [PubMed] [Google Scholar]
  7. Eilam Y, Silbermann M, Szdel N (1980) Growth inhibition of clonal osteosarcoma cell-lines by low concentrations of glucocorticoid hormones. Biochem Biophys Res Commun 96:299–305 [DOI] [PubMed] [Google Scholar]
  8. Fidler IJ (1984) Current concepts of cancer metastasis and their implications for therapy. Cancer Treat Rep 68:193–198 [PubMed] [Google Scholar]
  9. Fidler IJ (1987) Review: biological heterogeneity of cancer metastases. Breast Cancer Res Treat 9:17–26 [DOI] [PubMed] [Google Scholar]
  10. Fidler IJ, Poste G (1982) The heterogeneity of metastatic properties in malignant tumor cells and regulation of the metastatic phenotype. Tumor cell heterogeneity. Academic Press, New York pp 127–145 [Google Scholar]
  11. Heppner GH (1984) Tumor heterogeneity. Cancer Res 44:2259–2265 [PubMed] [Google Scholar]
  12. Heppner GH, Miller BE (1983) Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev 2:5–23 [DOI] [PubMed] [Google Scholar]
  13. Israel L (1990) Accelerated genetic destabilization and dormancy: two distinct causes of resistance in metastatic cells; clinical magnitude, therapeutic approaches. Clin Exp Metasasis 8:1–11 [DOI] [PubMed] [Google Scholar]
  14. Keppler BK, Berger MR, Klenner T, Heim ME (1990) Metal complexes as antitumor agents. Adv Drug Res 19:243–310 [Google Scholar]
  15. Klenner T, Wingen F, Keppler BK, Krempien B (1990a) Phosphonates with osteotropic and antineoplastic properties — a promising perspective in the treatment of bone-related malignancies? J Cancer Res Clin Oncol (in press) [DOI] [PMC free article] [PubMed]
  16. Klenner T, Wingen F, Keppler BK, Valenzuela-Paz P, Amelung F, Schmähl D (1990b) Therapeutic efficacy of two different cytostatic-linked phosphonates in combination with razoxane in the transplantable osteosarcoma of the rat. Clin Exp Metastasis 8, 345–359 [DOI] [PubMed] [Google Scholar]
  17. Klenner T, Keppler BK, Münch H, Valenzuela-Paz P (1990c) Treatment of rat osteosarcoma with phosphonic acid linked platinum complexes in vivo and in vitro. In: Collery Ph, Parier LA, Manfait M, Etienne JC (eds) Metal ions in biology and medicine. John Libby Eurotext, Paris, pp 369–371 [Google Scholar]
  18. Lollini P, De Giovanni C, Eusebi G, Nicoletti G, Prodi G, Nanni P (1984) High-metastatic clones selected in-vitro from a recent spontaneous BALB/c mammary adenocarcinoma cell line. Clin Exp Metastasis 2:251–259 [DOI] [PubMed] [Google Scholar]
  19. Miller BE, Miller FR, Heppner GH (1989) Heterogeneity of tumor cell sensitivities: implications for tumor responce. In: Chapman JB, Peters LJ, Withers RH (eds) Prediction of tumor treatment response. Pergamon Press, Elmsford NY, pp 227–238 [Google Scholar]
  20. Nanni P, De Giovanni C, Lollini P, Nicoletti G, Prodi G (1986) Clones with different metastatic capacity and variant selection during metastasis: a problematic relationship. JNCI 76:87–91 [PubMed] [Google Scholar]
  21. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194:23–28 [DOI] [PubMed] [Google Scholar]
  22. Poste G, Greig R (1983) The experimental and clinical implications of cellular heterogeneity in malignant tumors. J Cancer Res Clin Oncol 106:159–170 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Sekiya S, Iwasawa H, Yamauchi K, Kubota K, Takamizawa H (1981) Effect ofcis-dichlorodiammineplatinum (II) on cloned ovarian adenocarcinoma cells of the rat in-vitro. Gynecol Oncol 12:14–22 [DOI] [PubMed] [Google Scholar]
  24. Souhami RL (1989) Chemotherapy for osteosarcoma. Br J Cancer 59:147–148 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Tebbi CK, Gaeta J (1988) Osteosarcoma Pediat Ann 17:285–300 [DOI] [PubMed] [Google Scholar]
  26. Tsuruo T, Fidler IJ (1981) Differences in drug sensitivity among tumor cells from parental tumors, selected variants and spontaneous metastases. Cancer Res 41:3058–3064 [PubMed] [Google Scholar]
  27. Vogt-Moykopf I, Meyer G, Bulzebrück H, Merkle NM, Langsdorf M (1988) Indications and long-term results in surgery of pulmonary metastases. Contrib Oncol 30:76–107 [Google Scholar]
  28. Wingen F, Schmähl D, Berger MR, Spring H (1984) Intraosseously transplantable osteosarcoma with regularly disseminating pulmonary metastasis in rats. Cancer Lett 23:201–211 [DOI] [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES